EGFR and lung adenocarcinoma: In this study, we combined clinical factors and radiomic features based on contrast-enhanced CT images to predict acquired T790M mutation and survival in advanced lung adenocarcinoma patients with progression after first-line EGFR TKI–targeted therapy.